Eisai Boards Fast Boat To China In HER2-Targeting ADC Deal With Bliss

 
• By Alaric DeArment

The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate, as ADCs gain more interest from large pharma firms.

Eisai announced a deal with BlissBio for the Chinese company's HER2-directed ADC • Source: Shutterstock

More from Deals

More from Business